Big Market, Broad Plan: Bristol Shares Vision For Opdivo In Lung Cancer
Executive Summary
Releasing positive results for Opdivo in the Phase II CheckMate-063 study in highly refractory squamous-type NSCLC, Bristol explains its big tent development program, which tests the PD-1 inhibitor with immunotherapies as well as targeted drugs.